Leiomyoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Leiomyoma – Drugs In Development, 2024 report and make more profitable business decisions.
A leiomyoma, also known as a fibroid, is a benign smooth muscle tumor that very rarely becomes cancer. They can occur in any organ, but the most common forms occur in the uterus, small bowel, and the esophagus. It commonly affects individuals between menarche and menopause.
The Leiomyoma drugs in development market research report provide comprehensive information on the therapeutics under development for Leiomyoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Leiomyoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 15 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Leiomyoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Leiomyoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Leiomyoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncASKA Pharmaceutical Holdings Co Ltd
Bio Genuine
Daewon Pharmaceutical Co Ltd
Eurofarma Laboratorios SA
Evestra Inc
Foresee Pharmaceuticals Co Ltd
Immunitor Inc
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
Livzon Pharmaceutical Group Co Ltd
Northwestern University
Shijiazhuang Yiling Pharmaceutical Co Ltd
Synmosa Biopharma Corp
TiumBio Co Ltd
Xbrane Biopharma AB
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Leiomyoma reports